BGNE - BeiGene GAAP EPADS of -$2.41 beats by $0.48 revenue of $751.65M beats by $76.42M
2024-05-08 06:16:40 ET
More on BeiGene
- BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
- BeiGene, AbbVie patent spat to get trial from USPTO appeals board
- EU regulators approve BeiGene's tislelizumab for lung cancer
- Seeking Alpha’s Quant Rating on BeiGene
- Historical earnings data for BeiGene